Sixal is a company focused on the treatment of IgE-mediated disorders including food allergies, asthma and mastocytosis. In the US alone, a patient is admitted to the ER every 20 minutes with anaphylaxis due to food allergy. Food allergies annually affect 15 million in the US and 19 million in the EU. Sixal has developed a novel approach that employs the humanization of low affinity anti-IgE mAbs to design an optimal human therapy to mitigate allergic reactions that occur in asthma and severe food allergy. The down-regulation target in allergic disease has been validated by the work in Xolair® but the use of low affinity antibody is faster and more efficient.

Graduated in 2018